The latest deal over a CD47 asset has got investors wondering who could be next.
Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.
Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.
Boehringer Ingelheim struck a deal with the oncolytic virus company Viratherapeutics in 2016, and it has clearly seen something extraordinary in the intervening two…
Oncology-focused smaller biotechs reap rich rewards, but generics groups face hard times.